We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin.
- Authors
Arbab, Mona; Chen, Yu‐Hui; Criscitiello, Shana; Glass, Jason; Fugazzotto, Jo Ann; Killoran, Joseph H.; Hanna, Glenn; Lorch, Jochen; Haddad, Robert I.; Margalit, Danielle N.; Tishler, Roy B.; Schoenfeld, Jonathan D.
- Abstract
Background: Patient Reported Outcome (PRO) data comparing bolus (B‐CP) with weekly (W‐CP) cisplatin concurrent with radiation are lacking. Methods: We performed a retrospective study comparing PRO among 99 patients with head and neck radiation, 26% who received concurrent B‐CP and 73% treated with W‐CP. Results: W‐CP patients had a higher Charlson comorbidity index (CCI) (P =.004). There were no differences in median cisplatin dose, PROs, percutaneous endoscopic gastrostomy (PEG) dependence or hospitalization between arms. Patients with a greater decline in their self‐reported dysphagia score were more often PEG dependent at the end of radiation therapy (P =.03). There was also a trend toward PEG dependence with a higher maximum dysphagia score and greater change in aspiration score (P =.06). The maximum decline in white cell count and absolute neutrophil count were greater in the W‐CP group (P =.04, P =.01). Conclusion: Both B‐CP and W‐CP are well tolerated. PROs do not suggest a benefit to W‐CP.
- Subjects
PATIENT reported outcome measures; HEAD &; neck cancer; PERCUTANEOUS endoscopic gastrostomy; CHEMORADIOTHERAPY; LEUCOCYTES
- Publication
Head & Neck, 2020, Vol 42, Issue 12, p3670
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.26432